Our data estimated that IFN-related innate immune responses can be induced in the NP during the early phase of COVID-19 regardless of severity of infection and activation of innate immune responses in upper airway may provide a better therapeutic outcome of COVID-19 treatment. The gene discussed is IFNA1; the disease is COVID-19.